Body size can change the odds of metabolic problems. It cannot tell you with certainty how someone’s metabolism is working.
Imagine two adults with the same BMI.
On paper, their weight relative to height is identical. But one may carry more fat around the abdominal organs. Another may store more under the skin. They may have very different amounts of fat in the liver, different levels of physical activity, different family histories, and very different responses to insulin.
Now imagine two people in different weight categories. It is tempting to assume that the person with the lower BMI must also be more insulin-sensitive.
Across large populations, lower adiposity generally does mean lower risk. Overweight, obesity, and a larger waist are well-established risk factors for insulin resistance and type 2 diabetes.
But risk is not diagnosis.
So, yes: someone can have insulin resistance without having obesity.
That does not make body weight metabolically irrelevant. It means something more useful: body size can tell us something about risk, but it cannot tell us exactly how one person’s metabolism is working.
We can see body size. We cannot see insulin sensitivity.
Insulin Resistance Is Not a Weight Category
Insulin resistance describes how the body responds to a hormone, not what the body looks like.
Insulin helps regulate blood glucose. In insulin resistance, cells in tissues such as muscle, fat, and the liver do not respond as effectively to insulin. The body can compensate for a time, including by producing more insulin. If that compensation eventually becomes insufficient, blood glucose can rise.
That is different from prediabetes or type 2 diabetes.
Prediabetes means blood glucose is higher than normal but has not reached the diagnostic threshold for diabetes. Type 2 diabetes is diagnosed when glucose-related measures meet established criteria. Insulin resistance can contribute to both, but the terms are not interchangeable.
BMI measures something different again. It is calculated from weight and height. It does not directly measure insulin action, body-fat distribution, or even body fat itself.
That limitation is not an argument for throwing BMI away. It is a reason to use it for what it can actually tell us.
BMI is simple, inexpensive, and meaningfully associated with health risk across populations. But current clinical guidance recognizes that it can misrepresent adiposity in some individuals and cannot show where body fat is stored.
That is the first reason the apparent contradiction disappears.
A person can fall outside a BMI category associated with obesity and still have impaired insulin sensitivity because BMI and insulin resistance are measuring fundamentally different things.
But if that is true, why are obesity and insulin resistance so closely connected?
Weight Matters—Just Not in the Way We Sometimes Assume
The wrong lesson would be that weight has little to do with metabolic health.
It does.
Greater adiposity, particularly around the abdomen, is associated with higher risk of insulin resistance and type 2 diabetes. Current diabetes guidelines therefore treat overweight, obesity, and central adiposity as important pieces of metabolic risk assessment.
But population risk and individual diagnosis are not the same thing.
Age offers a useful comparison. Type 2 diabetes becomes more common with age, and current guidelines recommend routine screening beginning by age 35 even in adults who do not otherwise meet risk-based criteria.
That does not mean every older adult has diabetes or every younger adult is protected.
Age changes probability.
Body composition works similarly. Greater adiposity can substantially shift metabolic risk without determining the metabolic status of every individual.
Some people with obesity are more insulin-sensitive than others with a similar BMI. Conversely, metabolic abnormalities can occur in people whose BMI is below the obesity range.
And one major reason is that BMI leaves out something metabolically important:
where the fat is.
Two People With the Same BMI Can Store Fat Very Differently
A scale tells you how much someone weighs. BMI adjusts that number for height.
Neither tells you where body fat is stored.
Some fat sits beneath the skin. Some accumulates deeper in the abdomen around internal organs—visceral fat. Fat can also accumulate in organs such as the liver.
Those differences can matter metabolically.
Research using imaging to distinguish fat compartments has found associations between insulin resistance and abdominal and liver fat that cannot be captured by body weight alone.
That does not mean liver fat or visceral fat single-handedly determines someone’s insulin sensitivity. Nor does it mean everyone needs an imaging scan to map their body fat.
It means two bodies with the same BMI are not necessarily metabolically equivalent.
Current clinical guidance increasingly reflects that limitation. The ADA recommends BMI for screening while allowing additional measures of adiposity and body composition when appropriate; its 2026 obesity guidance explicitly notes that BMI does not directly evaluate body composition or fat distribution.
Waist measurements can add information about central adiposity, but they are not direct tests of insulin sensitivity either.
They improve the risk picture.
They do not make metabolism visible.
And fat distribution is only part of the reason people differ.
Body Size Is Only One Part of Metabolic Risk
Two people could have similar body size and still have different risks of abnormal glucose regulation.
Family history, age, physical activity, medical conditions, and some medications can all matter. Current ADA screening criteria include factors such as a first-degree relative with diabetes, cardiovascular disease, hypertension, abnormal blood lipids, polycystic ovary syndrome, physical inactivity, and conditions associated with insulin resistance. Certain medications can also increase the risk of abnormal glucose regulation.
None of those factors proves that someone has insulin resistance.
They change the odds.
Physical activity also shows why metabolism and body size do not always move together. Muscle is a major site of glucose disposal, and its response to insulin is influenced by activity and other physiological factors. A person does not have to cross into a different BMI category before their metabolic function can change.
The larger point is simple.
BMI contains useful information, but not enough information to describe an individual’s metabolic health.
That is why replacing “weight determines metabolic health” with “weight doesn’t matter” would simply trade one bad shortcut for another.
You Can’t Diagnose Metabolic Health by Looking at Someone
This is where the distinction becomes practical.
A person whose BMI falls below the obesity range should not assume that this guarantees normal glucose regulation or permanent protection from type 2 diabetes.
But the opposite assumption is unreliable too: having obesity does not, by itself, prove that a particular person has insulin resistance.
Current diabetes-screening recommendations make this clear. Adults of any age with overweight or obesity plus additional risk factors should be considered for testing. For other adults, routine screening begins at age 35 regardless of whether they have overweight or obesity.
If lower body weight reliably excluded metabolic problems, that broader screening recommendation would make little sense.
The standard clinical tests include A1C, fasting plasma glucose, and the oral glucose tolerance test. These identify abnormal glucose regulation and diabetes; they are not direct measurements of how sensitive every tissue in the body is to insulin.
That distinction matters because discussion of insulin resistance can easily create the impression that everyone needs a special insulin test or a consumer-facing “insulin resistance score.”
Routine diabetes screening does not work that way. Clinical guidance focuses on established risk assessment and validated tests for abnormal glucose regulation rather than trying to directly measure insulin sensitivity in everyone.
Nor should a single normal glucose result be interpreted as proof of “perfect” insulin sensitivity. A test answers the clinical question it was designed to answer.
The useful lesson, then, is not to become suspicious of people who look lean or dismissive of the well-established metabolic risks associated with excess adiposity.
It is to stop asking appearance to perform a job it cannot do.
We can see body size. We cannot see insulin sensitivity.
Obesity and central adiposity meaningfully increase metabolic risk. That relationship is real and clinically important. But insulin sensitivity also varies with fat distribution, physical activity, age, family history, medications, health conditions, and other individual factors.
That is why two statements that can sound contradictory are both true:
Body size matters for metabolic risk. And body size alone cannot tell you someone’s metabolic status.
So yes, someone can have insulin resistance without having obesity.
The larger lesson is more useful than that fact alone:
Metabolic health is something the body does—not something you can reliably determine by looking at the body.
